

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD)

FOR THE YEAR ENDED 31 DECEMBER 2023

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 20 March 2024 (the “**Announcement**”) in relation to the annual report for the year ended 31 December 2023 of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the year ended 31 December 2023 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

**PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF
SINOPHARM (CNCM LTD)**

*Unit: Yuan
Currency: RMB*

	Year of 2023	Year of 2022	Changes of this year compared with last year (%)	Year of 2021
Revenue	49,696,045,528.87	45,498,583,764.24	9.23	46,468,602,844.57
Net profit attributable to shareholders of the listed company	2,145,998,746.54	1,964,057,559.33	9.26	1,754,084,218.80
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	2,092,945,826.67	1,910,981,633.08	9.52	1,691,583,326.79
Net cash flow arising from operating activities	2,726,657,097.53	2,395,123,454.99	13.84	1,957,451,032.00
Basic earnings per share (Yuan/Share)	2.8443	2.6031	9.26	2.3248
Diluted earnings per share (Yuan/Share)	2.8443	2.6031	9.26	2.3248
Basic earnings per share after deducting non- recurring gains and losses (Yuan/Share)	2.7739	2.5328	9.52	2.2420
Weighted average return on net assets (%)	13.68	14.65	Decreased by 0.97 percentage point	14.57
Weighted average return on net assets after deducting non-recurring gains and losses (%)	13.34	14.25	Decreased by 0.91 percentage point	14.05
	At the end of 2023	At the end of 2022	Changes of 2022 year-end over 2021 year- end (%)	At the end of 2021
Net assets attributable to shareholders of the listed company	15,775,887,678.80	14,214,807,659.39	10.98	12,779,969,993.44
Total assets	32,453,092,592.42	29,609,041,999.59	9.61	28,010,057,725.04

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
20 March 2024

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.